“Russia can have as many nuclear cases as you like, but since the 500 billion dollars of the Russian elite are in our banks, you can figure it out: is it your elite or is it ours?”
Z. K. Brzezinski, US Presidential Advisor on National Security
Z. K. Brzezinski, US Presidential Advisor on National Security
From the editors. We recommend that you familiarize yourself with this work, since its author, even if forced to act under a pseudonym, is a real expert, unlike many who demonstrate their opinion. Set out in this material makes us look differently at real threats to us. Yes, the article is presented specifically, but the time you spend reading, understanding and comprehending will be worth it.
* * *
The situation with the spread of COVID-19 in the Russian Federation and on the planet very sharply (even in peacetime, not to mention military time) raised the question regarding the ability of the state and society to organize and effectively respond to an urgent biological threat.
Today, the COVID-19 epidemic is developing in the Russian Federation in a relatively peaceful time, when our rulers can, with a view to gaining personal political points, help NATO countries in matters of anti-infection protection, and NATO countries do not seek to openly increase the scale of the spread of COVID-19 in the Russian Federation.
But do not forget that the NATO countries (at least their main core) are our geopolitical enemies, I will not be afraid of the word, from the “beginning of time”, to this day and for the foreseeable future, as long as they exist in their cultural tradition that we have not destroyed .
Against the background of an inflated soap bubble about the threat of COVID-19 to the entire world community and life on Earth, within the framework of this material, I would like to talk about another, much less noticeable, spreading for many years across our country and continuing to gain strength biological threat.
It will be about antibiotic resistance (insensitivity of pathogenic bacterial flora to antibiotics) and its economic and socio-political persons in the Russian Federation.
Today, the situation with both antibiotic resistance and the presence and prospects of the presence of effective antibacterial drugs in the Russian Federation is catastrophic.
The main problem is not even antibiotic resistance itself, but how monstrous it may sound that it was created and continues to consciously increase along with other drug problems by the authorities of the Russian Federation in close contact with the so-called business.
We are talking about activities in this vein of both the legislative and executive branches of the Russian Federation.
Already today, the situation with the “elites” imposing the healthcare of Russia through the authorities of the Russian Federation and the “business” that has grown together with them of the cheapest medicines and antibiotics, in particular, under the guise of the import substitution slogan, is in the long run a veiled attempt to systematically undermine the national security of the Russian state .
In the medium term, the continuation of such a policy poses no less threats to the existence of our country, which may unfold in an avalanche-like manner, unlike the first option.
For example, in the event of a military conflict of even moderate intensity, the Russian Federation runs the risk of suffering enormous losses not so much from direct hostilities as from the death rate of personnel from infections due to injuries.
Let's not forget that the personnel are, first and foremost, the most able-bodied and healthy young people, whose significant decline will even more rapidly throw the country into the demographic abyss without the slightest chance of ever escaping from there.
Also, one should not forget that the personnel in the Russian Federation are primarily Russians, with all the ensuing consequences for the Russian people in this country.
Actually, let's get down to business.
According to fig. 1, the cumulative resistance of the main causative agents of nosocomial (nosocomial) infections (nosocomial infections) in the Russian Federation ranges from 50 to 60%.
At the same time, our main opponents in North America and Western Europe, this figure does not exceed 30-40%, and in many of them it is at the level of 10-20%, as, for example, it looks in Canada, France or Germany.
It should be borne in mind that the total economic and production potential of the enemy is immeasurably greater than the corresponding Russian figure.
It turns out that in Russia in 2018 only 40-50% of pathogens are sensitive to major antibiotics, the rest are insensitive.
In terms of people, this means that from concomitant infections, on average 50% of the wounded are at risk of dying, in fact there is a risk, which is significantly greater.
Pathogens of nosocomial infections (nosocomial infections) are primarily insensitive to antibiotics.
In wartime conditions, wound non-sterility, general unsanitary conditions, decreased immunity due to malnutrition and increased psychoemotional stress in personnel, as well as the need for varying degrees of prolonged hospital stay, any wound, with the exception of the lightest ones, is at risk of degenerating into a resistant infectious process against the background of a developed nosocomial infection. The clinical significance of nosocomial infections is difficult to overestimate, Fig. 2:
As can be understood from Fig. 2, despite the fact that the frequency of sepsis with community-acquired pneumonia is higher than with nosocomial, the frequency of severe sepsis with nosocomial pneumonia is almost 3 times higher than with community-acquired pneumonia, the frequency of septic shock is more than 4 times higher.
Accordingly, both mortality and healthcare costs for the treatment of the effects of resistant nosocomial infections are significantly higher.
The current situation with nosocomial infections in the Russian Federation, according to Yakovlev S.V., president of the Alliance of Clinical Chemotherapists and Microbiologists, professor of the Department of Hospital Therapy No. 2, University Medical Therapy Clinic THEM. Sechenov, the following:
- the number of patients hospitalized annually in Russia is 30;
- the prevalence of nosocomial infections in Russian hospitals is 7,61%;
- in absolute figures, the estimated frequency of nosocomial infections is about 2 cases per year;
- The total economic damage caused annually by the NWI in the Russian Federation amounts to 300 billion rubles (5 billion US dollars).
It was indicated above that mortality due to nosocomial infections is significantly higher than against a background of a normal bacterial infection of the same localization caused by a non-resistant pathogen.
For a more complete understanding of the situation with infectious diseases in the Russian Federation, it makes sense to refer to a comparison of mortality data from these diseases between Russia and at least eight “new” EU countries: the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia and Slovenia, fig. 3:
SCS is a standardized indicator of mortality.
Mortality from infectious diseases in the Russian Federation in 2016 is 3,6 times higher than in the "new" EU countries!
Considering that the actual figures for the prevalence of nosocomial infections in Russia are closed, taking into account the above data, I suggest the reader to independently estimate what the real possible numbers of deaths from nosocomial infections in the Russian Federation are, if mortality from infectious diseases as such in our country is 22,3 patients per 100 population .
There is a possibility that you can easily multiply by 3.
Some general information, fig. 4:
And how are things with the at least some of these pathogens in the Russian Federation today?
The main causative agents of nosocomial infections of the family of enterobacteria in Fig. 5:
1. Escherichia coli (E.coli).
2. Klebsiella pneumonia (K. pneumoniae).
3. Enterobacter (Enterobacter spp.).
Over a period of about 14 years (1997–2011), the resistance of enterobacteria to cephalosporins of the 3rd-3th generations in the Russian Federation increased almost 6 times, while the ability of representatives of this family to produce ESBL (extended-spectrum beta-lactamases, or BLRS) increased than XNUMX times, fig. XNUMX.
Due to beta-lactamase, the bacterium survives by cleaving an antibiotic directed against it.
Cephalosporins of the III-IV generations along with carbapenems are the main antibiotics of a wide spectrum of action used in the Russian Federation.
The main palette of antibiotics and the frequency of their use in hospitals of the Russian Federation in dynamics against the background of an increase in antibiotic resistance, Fig. 7, 8:
How much the problem continues to remain relevant can be understood by comparing the research data of RIORITA (2009) and ERGINI, 2013:
“The presence of the III-IV generation cephalosporins and fluoroquinolones in the structure of the prescribed first-line antibiotics is surprising and certain concern (a total of 42,3%). Those. about 50% of patients with nosocomial infections receive inadequate therapy. ”
In fact, not only are nosocomial infections caused by resistant flora, they also try to influence this flora not somewhere, but in a hospital setting, they try antibiotics, which in most cases not only do not work against it, but also contribute to enhancing its stability !
Here it should be noted that we are not even talking about district hospitals, but about regional centers of subordination above. It is in hospitals of this level that patients with nosocomial infections are located.
The situation with the preservation of the prescription of those antibiotics, to which the majority of nosocomial infections are resistant, is already a question not so much of providing the hospitals of our country with adequate antimicrobials, but of the quality of the current medical education after brilliant government reforms.
The situation with enterobacteriaceae resistance to carbapenems (Fig. 9) looks a little better than with cephalosporins resistance shown in Fig. 5 (see above).
Over a period of 9 years (2002–2011), the resistance of enterobacteria to carbapenems (depending on the representative) increased from 2,1 to 2,8 times, the ability to produce carbapenemases increased by 3,7 times.
The only antibiotic to which the acceptable sensitivity of enterobacteria is preserved is polymyxin E or its fellow polymyxin B, Fig. ten.
Moreover, not one of them is produced in the Russian Federation - it is only repackaged!
* AMT - antimicrobial therapy.
After a comprehensive review of the situation with antibiotic resistance in the Russian Federation for this group of pathogens, it will not be superfluous to compare this situation with that of our sworn friends, according to the same indicator, Fig. eleven:
H - sensitive; UR - conditionally resistant, P - resistant.
According to AMRmap data for 2015, the share of BLRS producers among enterobacteria in the Russian Federation is 80,28% (together with conditionally resistant flora), which is 3,35 times higher than in the USA!
Summarizing the data in Fig. 6, 9 and 11, to summarize:
1. In Russia, 2011-2012. the proportion of BLRS producers among enterobacteria was 78,2%, which is more than 3 times higher than in the United States over the same period.
2. In 2015, in the Russian Federation this share increased to 80,28%, exceeding the figure by 3,4 times relative to the United States, despite the fact that, according to AMRmap, the situation with resistance in the United States has not changed!
The share of carbapenem-resistant (CRC) enterobacteria in the Russian Federation is on average 8,4%, which is also higher than in the USA (7%), see Fig. 12.
Among enterobacteria, Klebsiella is the most resistant to antibiotics.
The growth dynamics of Klebsiella resistance to carbapenems against the background of the use of generic copies instead of the original drugs is very curious:
If in 2011, against the background of using the original carbapenems, the total resistance to them of K. pneumoniae in a particular hospital (St. Alexis Hospital, Moscow) was 6%, then in 2014 (in just 3 years (!)), When the share of generic carbapenems was more than 95% of their total number, K. pneumoniae resistance has become equal to 31% (resistance dynamics - more than 5 times!), Fig. 13.
According to the data of the PROFESSIONAL MEDICAL ASSOCIATION OF CLINICAL PHARMACOLOGISTS OF ST. PETERSBURG, 2014:
“Generic drugs in Russia - about 70% of all drugs, including antibiotics. These are both “domestic” antibiotics and antibiotics from the “third world” countries, the effectiveness and safety of which raise a big question.
At present, we cannot control, and therefore, guarantee the quality of therapy with these drugs, especially in terms of safety. "
At present, we cannot control, and therefore, guarantee the quality of therapy with these drugs, especially in terms of safety. "
For your information:
Currently, 98 INN (international nonproprietary name) of antibacterial drugs for systemic use, which have 755 (!) Trade names (TH), are issued in the amount of 8588 medicinal products (LP) by 240 companies Consulting Pharma, June 2018).
Above, we compared the situation in the Russian Federation with the “new” eight EU countries.
I can assure you, dear readers, that such bacchanalia with antibiotics are not observed in any of these countries, all the more so in the “old” EU countries, not to mention the United States.
But the business of elites is the business of elites, under the slogan of import substitution or in parallel with it. What is the business of the doctor’s needs or the patient’s real needs, read: the country's population? Which of the doctors or patients in our country needs the presence on the market of 16 trade names of the same INN - vancomycin?
Why not leave only three, as is done in the same EU or US?
Is it competition and a free market, or is there a poorly hidden desire to snatch another piece, even at the cost of the mediated genocide of the population of this country, under these already-worn-out mantras of the powers that be?
The data of the ASSOCIATION OF CLINICAL PHARMACOLOGISTS OF ST. PETERSBURG are completely consistent with the data of the HIGH SCHOOL, 2019, Fig. fourteen.
The general situation with the consumption of generic drugs in the Russian Federation in comparison with other countries:
So, among all (!) OECD countries (Organization for Economic Co-operation and Development), the share of consumption of generic copies of medicines in the Russian Federation is 2,5 times higher in monetary terms and 1,6 times in kind in comparison with EU countries 88% in packages and 64% in money.
In this context, it is worth mentioning an article by R. Skomorokhov that was previously published on the VO “What will kill us? Well, definitely not the Tomahawks, where the causal relationship is clearly spelled out, to whom and for what reason it is beneficial that Russia consumes generics and that the growth in the number of these generics in our market is absolutely uncontrolled.
In fig. 14 dear readers can see the results of the implementation of this causal relationship in concrete, with fresh figures.
In this case, one can already clearly see the real scale of the disaster and at the same time estimate its prospects for the future, moreover, not projecting all this abstractly onto the hypothetical population of the Russian Federation, but extrapolating it specifically to itself and its loved ones, as, for example, R. Skomorokhov did it.
We have already mentioned the effectiveness and safety of generic drugs on the market of the Russian Federation above.
Another causative agent of resistant nosocomial infection is acinetobacter, Fig. fifteen.
Between 2002 and 2013 (11 years), A. baumannii's resistance to carbapenems (depending on the representative) increased from 6,3 to 11,8 times. The share of carbapenemase-producing strains of A. baumannii over the same period increased by more than 25 times (!).
Another problem associated with acinetobacter is the high frequency of the associated resistance of this pathogen to antibiotics of other groups.
Among A. baumannii extreme resistant (XDR) strains - 54%, pan-resistant (PDR) - 27%.
The only antibiotic to which the acceptable sensitivity of microorganisms of the A. baumannii family is preserved is polymyxin E or its fellow polymyxin B, Fig. 16. Once again I repeat, not one of them is produced in the Russian Federation - it is only repackaged.
The share of carbapenem-resistant (CRC) of A. baumannii in the Russian Federation is 72,8% (1,2 times higher than in the USA: 72,8% versus 61%, see Fig. 17).
Considering the pace of resistance of A. baumannii, as well as the share of XDR and PDR of A. baumannii strains, it should be noted that the difference of 1,2 times between the Russian Federation and the USA is a very significant difference.
In its socio-economic consequences, it may be equivalent to a difference of 5 times for Pseudomonas aeruginosa.
Pseudomonas aeruginosa bacillus Pseudomonas.
Between 2002 and 2011 (9 years), P. aeruginosa resistance to carbapenems (depending on the drug) increased from 1,2 to 2,3 times, Fig. 18. At the same time, the share of P. aeruginosa producing MBL over the same period increased 6,3 times, Fig. 18.
It should be noted that bacteria producing MBL are microorganisms that are most resistant to antibiotic therapy.
And again, the only antibiotic to which the acceptable sensitivity of Pseudomonas aeruginosa containing MBL is maintained is polymyxin E or its fellow polymyxin B, Fig. 19.
Fig. 20, resistance of Pseudomonas aeruginosa (not MBL) to:
- aminoglycosides - more than 60,2% (5,5 times higher than in the USA: 60,2% against 11%);
- cephalosporins of the III generation - 60,9%;
- IV generation cephalosporins - 58,9% (2 times higher than in the USA: 58,9% versus 28%);
- fluoroquinolones - 69,2% (2,1 times higher than in the USA: 69,2% against 33%);
- carbapenem - 77,4% (2,6 times higher than in the United States: 77,4% against 30%);
- piperacillin / tazobactam - 67,3% (3,5 times higher than in the US: 67,3% versus 19%).
Staphylococcus aureus (Staphylococcus aureus) is another representative of the resistant microbial flora.
Staphylococcus is primarily an infection of the skin, soft tissues, heart and blood vessels, as well as bones and joints.
MRSA - a stable, poorly succumbing to conventional antibiotic therapy wound staphylococcal infection in all its glory.
Until 2017, a steady increase in the proportion of MRSA was observed, Fig. 21, after which this trend began to decline. Nevertheless, the problem of resistant staphylococcal infections continues to remain relevant. Unlike the pathogens discussed above, staphylococcus is a gram-positive infection. Most often, vancomycin and linezolid are used to combat resistant gram-positive flora in our country.
Moreover, of the 15 companies selling vancomycin molecule in Russia under various trade names, Synthesis OJSC (Kurgan) is the only company, according to the data of the State Pharmacological Administration, which independently produces a pharmacological substance for the production of this drug. All other Russian manufacturers use Indian or Chinese substances.
The situation in our country is similar with linezolid.
Not so long ago, at the end of 2018, another drug for the fight against gram-positive infection appeared in the Russian Federation - Ortotsid (Kraspharma PJSC), INN-teicoplanin.
The whole charm of the situation is that PJSC “Krasfarma”, trying to add its teicoplanin to the formulary lists of hospitals and regions, cannot provide data even from registration studies! How teicoplanin PJSC "Krasfarma" was admitted to circulation on the territory of the Russian Federation, without having passed the registration studies necessary for this, one can only guess.
Accordingly, questions of the effectiveness and safety of this drug, which should be demonstrated in comparison with the original drug as part of a registration study, are hidden in the dark.
But at the same time, orthocide is sold on the Russian pharmaceutical market, and Kraspharma PJSC is actively promoting it in tenders for procurement by hospitals in order to treat severe and debilitated patients with resistant staphylococcal infection!
This is a drug for which there is no evidence of its safety, confirmed even in the registration study, not to mention post-marketing, and which can be dangerous even for healthy volunteers, not to mention exhausted patients with nosocomial infection!
How things are with the proven effectiveness of this drug, I believe readers themselves are able to think out.
Against the background of all of the above, the situation with scientific research in our country is curious, which, logically, should have been aimed at creating new drugs at least within the framework of the import substitution program.
What’s called, hello, our dear Chubais, hello, dear Skolkovo!
Russia in comparison with other countries in R&D in the field of drug development, fig. 22.
R&D for new drugs in the Russian Federation amounts to 0,04% of GDP, which is 3 times less than in the “new countries” of the EU. Let me remind you that this is the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia and Slovenia.
We are not talking about a comparison with the United States: the difference is only 10% in percentages; in absolute terms, it is generally incommensurable.
The situation in Russia compared to the Republic of Korea, 2017, is shown in Fig. 23.
Please note that the absolute figures of funds allocated in Russia for this direction are unknown, most likely classified.
It’s like with the real estate of our elites, just the opposite: there are mansions, but the Rosreestr is hidden from curious citizens who they belong to, and here there is a lack of money for the needs of citizens, but the extent of this absence is also carefully hidden from curious citizens.
Such is the care of the rulers about our psycho-emotional health and mental balance, such as “you know less, sleep better” and first of all you are not distracted from the main task of your existence - to create all kinds of benefits for them in the shortest possible time with minimal cost.
The results of the Korean R&D program in the field of drugs, 2017 look impressive, Fig. 24:
Summing up the review of the situation with antibiotic resistance in Russia as one of the threats to the country's national security, it makes sense to once again recall the article “What will kill us?” Well, definitely not the Tomahawks.
This article mentions Kathrin Eban, author of "Bottle of Lies". There is a brief retelling of the contents of the book on the net: cm. here.
In this retelling for us as residents of Russia at the moment it is important not even that the substances for drugs are made not in our country, but in India or China, but that the worst quality goods are dumped from India and China to Russia along with with the most backward countries of Africa and, naturally, Ukraine.
The most disgusting thing is that all our “bonzes” are well aware of this and not only continue to cover this process, but in every way contribute to its expansion, in parallel and absolutely consciously, under the guise of ostentatious import substitution, blocking access to quality medicines to the country.
And here the question is not so much that the “bonzes” against the background of this process are actively filling their pockets, most likely this is a side effect, a kind of comforting prize for them to implement, but rather that through the process itself they perform a specific, say frankly, religious and ideological order.
What is the ultimate goal of this order is not hard to guess.
What Kathrin Eban says in his book is clearly demonstrated in Russia using the example of the hospital named after St. Alexy, owned by the Moscow Patriarchate (see. Fig. 13) and this is not in some distant past, but in the present!
This is Moscow, but what about the regions?
I draw your attention to the fact that the hospital is owned by the Russian Orthodox Church, therefore, it does not participate in government procurement and is not forced to buy the cheapest drugs!
How many deaths did this artificially generated antibiotic resistance produce only in this health care facility?
How many deaths did she give rise to and will give rise to where they are forced to buy only the cheapest drugs, because it says No. 44-FZ designed for "our good"?
The size of budgets for the purchase of drugs and the directions of their development in health facilities is a separate issue altogether!
I won’t even touch her here! Although all this is interconnected.
How many children were not born or died only before the 1st year of life from resistant infections due to non-working drugs or effective work of doctors from the “Topilin list”?
How many survivors of this age will die or become disabled afterwards, against the background of the accompanying carefully cultivated social ill-being?
How many survivors after this will be able to give birth and all the more fully raise their children?
What will be the proportion of these children compared to their previous surviving parents?
How many women, Russian women, primarily against the background of inflammatory processes and their chronicity, did not or will not become mothers?
Yes, just for this, expensive perinatal centers are being created in parallel, which, on the one hand, suck out huge amounts of money from the budget, pouring money in a large percentage of cases of the living dead, and on the other hand, they serve as a kind of picture for the people who care for those in power citizens with absolute futility in terms of maintaining and increasing real fertility in the country.
The fact that due to the work and creation of these centers is a serious enrichment of a certain circle of people and their close associates, I do not even mention.
Here, in fact, is the geometrical progression of the situation, designed to free the territories from the ideologically irregular bipedal biomass, its culture and everything connected with it.
Everything is absolutely environmentally friendly.
You just need to inherit!
And if you and I previously discussed a threat to national security in connection with possible hostilities, now, as you can see, simply due to the daily activities of the healthcare system of the Russian Federation and the hostilities it is not necessary for a large-scale deployment of this threat.
And this applies not only to the situation with medicines.
This is the national staff of doctors, this is the general education system and the medical education system, in particular, as its superstructure, and much more.
At the moment, the situation prevailing in Russia in the 20s of the XNUMXth century is being repeated: the planned large-scale (multi-way and diverse) genocide of the Russian people, simply by other methods, while not only no less, but much more effective, given their secrecy, effectiveness, as well as comprehensive profitability for interested parties, which motivates them to unlimited expansion of their activities in all directions against the background of a planned, approved and fully tangible gesheft.
The necessary afterword. For those who are fully acquainted with the material. The text is very heavy and abounds with many specific terms that are not characteristic of our publication. However, from the point of view of the expert (and the editorial board fully supporting him), this material is no less topical than the new samples weapons at "potential" opponents.
Moreover, today it is very difficult to say whether it is worse to fight: with non-modern weapons or with modern antibiotics. And from which there will be more loss.